心臓バイオマーカーの世界市場予測（～2030年）：製品タイプ、検査場所、用途、エンドユーザー、地域別の分析

世界の心臓バイオマーカーの市場規模は、2023年に187億米ドルを占め、予測期間中にCAGR16.6％で成長し、2030年には548億米ドルに達すると予想されています。 心臓バイオマーカーは、心臓の傷害、損傷、ストレスによって血流中に放出される特定の分子やタンパク質です。

トロポニン、クレアチンキナーゼ-MB（CK-MB）、B型ナトリウム利尿ペプチド（BNP）などのバイオマーカーは、心臓関連の状態を示す診断に使用されます。これらの検出値や濃度は、心臓発作、心不全、その他の心疾患の診断、治療方針の決定、心臓の健康状態の評価に役立っています。

世界保健機関（WHO）によると、18歳以上の成人7,700万人が2型糖尿病であり、2,500万人が糖尿病予備軍です。これは心血管疾患のリスクを高め、医療システムにさらなる負担をかけています。

心血管疾患の増加

心筋梗塞、心不全、心臓虚血などの心臓関連疾患の世界的な負担の増加に伴い、信頼性の高い診断ツールに対する需要が高まっています。心臓バイオマーカーは、心血管疾患の早期発見、診断、予後に役立つ重要な指標となります。心臓の健康状態を正確に評価し、リスクを予測し、治療戦略を導くその能力は、世界中で増加する心血管疾患の発生率に対抗するための、効率的でタイムリーかつ正確な診断に対する差し迫ったニーズと一致しています。

厳しい規制

厳しい規制が心臓バイオマーカーの開発と実用化を阻んでいます。規制当局が定める厳格な承認プロセスでは広範な臨床検証が要求されるため、新規バイオマーカーの市場投入までの期間が長期化することが多いです。このような厳しいガイドラインでは、心臓疾患の検出における正確性、感度、特異性を確保するための包括的な研究が必要となります。これらの規制を遵守するためには、調査、臨床試験、特定の性能基準を満たすための多額の投資が必要となり、コストと時間の制約が増大します。

ポイントオブケア検査への注目の高まり

ポイントオブケア検査は、迅速かつ簡便な現場での診断を可能にし、中央検査室に検体を送ることなく即座に結果を得ることができます。心臓治療では、これによりトロポニンのようなバイオマーカーの迅速な検出が可能になり、心臓発作のような心臓疾患の迅速な診断が可能になります。このシフトは、特に救急現場での治療決定を迅速化することによって患者ケアを向上させ、また、ターンアラウンドタイムを短縮し、心臓救急の管理における全体的な効率を改善することによって医療システムをサポートします。

代替診断法の出現

高度な画像診断技術やポイントオブケア検査機器などの新しい技術は、心臓の健康状態を評価するための、迅速で非侵襲的な、そしておそらくはより費用対効果の高い方法を提供する可能性があります。このような代替技術は、従来のバイオマーカー検査の優位性に挑み、市場の採用や医療提供者の嗜好に影響を与える可能性があります。

COVID-19の影響：

COVID-19の大流行は、医療資源をウイルスの管理に振り向けることで、心臓バイオマーカー検査に影響を与えました。COVID以外の受診が減少したため、心臓の評価が少なくなり、バイオマーカー検査の頻度に影響を与えました。さらに、COVID患者の一部は心臓合併症を経験し、バイオマーカー評価の需要が増加しました。パンデミックによる医療システムへの負担は優先順位を変え、心臓バイオマーカーの利用率に影響を与え、健康危機時の適応可能な診断戦略の必要性を強調しました。

予測期間中、トロポニンセグメントが最大になる見込み

トロポニンセグメントは、心臓関連疾患の診断のための高感度かつ特異的な心臓バイオマーカーとして広く使用されているため、優位を占めると予測されます。トロポニン、特にトロポニンIとトロポニンTは、心筋傷害の検出において優れた感度を示し、特に心臓発作の診断に有用です。世界の心血管系疾患の有病率の増加と日常臨床におけるトロポニン検査の採用増加により、予測期間中、トロポニン検査は心臓バイオマーカー検査の最大セグメントとなることが予想されます。

病院セグメントは予測期間中最も高いCAGRが見込まれる

病院セグメントは、病院環境における高度医療サービスや診断施設への患者アクセスの増加により、大幅な成長が見込まれています。病院は急性期医療の主要なセンターとして機能しており、心臓バイオマーカー検査は心臓関連の疾患の診断において極めて重要な役割を果たしています。心血管疾患の罹患率の上昇と、病院環境におけるタイムリーで正確な診断の必要性が、このセグメントの予想成長に寄与しています。

最大のシェアを占める地域

北米が心臓バイオマーカー市場で優位を占めると予想されるのは、確立された医療インフラ、技術の進歩、高い医療費に起因します。同地域の強固な研究開発活動と主要市場企業の存在が、同市場の大きなシェア獲得に寄与しています。さらに、心血管疾患の有病率の高さと、先進的な診断技術に対する意識の高まりや導入が、市場の成長を後押ししています。

CAGRが最も高い地域

アジア太平洋は、心血管疾患の有病率の増加、高齢化人口の増加、医療インフラの改善により、心臓バイオマーカー市場の大幅な成長が見込まれています。同地域では心臓の健康に対する意識が高まっており、高度な診断ツールに対する需要が高まっています。さらに、政府や医療機関による心臓ケアの強化に向けた取り組みも市場拡大に寄与しています。中国やインドのような国々で心臓バイオマーカーの採用が増加しており、医療技術の進歩とともに、アジア太平洋は著しい市場成長を遂げる見通しです。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の心臓バイオマーカー市場：製品タイプ別

• B型ナトリウム利尿ペプチド（BNP）
• クレアチンキナーゼ- 筋肉/脳（CK-MB）
• 高感度 C反応性タンパク質（hs-CRP）
• ミオグロビン
• トロポニン
• その他の製品タイプ

第6章 世界の心臓バイオマーカー市場：検査場所別

• ポイントオブケア検査
• 臨床検査

第7章 世界の心臓バイオマーカー市場：用途別

• 心筋梗塞
• うっ血性心不全
• 急性冠症候群
• その他の用途

第8章 世界の心臓バイオマーカー市場：エンドユーザー別

• 診断研究所
• 病院
• 製薬会社およびバイオテクノロジー会社
• 研究機関
• その他のエンドユーザー

第9章 世界の心臓バイオマーカー市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 協定、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Abbott Laboratories
• Beckman Coulter
• Becton, Dickinson and Company（BD）
• BG Medicine
• Bio-Rad Laboratories
• Corgenix
• Fujirebio
• Hologic
• Meso Scale Diagnostics（MSD）
• Mindray
• Ortho Clinical Diagnostics
• Pathkind Labs
• Qiagen
• Randox Laboratories
• R-Biopharm AG
• Response Biomedical
• Roche Diagnostics
• Siemens Healthineers
• Singulex Inc
• SRL Diagnostics
• Thermo Fisher Scientific
• Trinity Biotech

List of Tables

• Table 1 Global Cardiac Biomarkers Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 3 Global Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 4 Global Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 5 Global Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 6 Global Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 7 Global Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 8 Global Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 9 Global Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 10 Global Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 11 Global Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 12 Global Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 13 Global Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 14 Global Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 15 Global Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 16 Global Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 17 Global Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 18 Global Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 19 Global Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 20 Global Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 21 Global Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 22 Global Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 23 North America Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 24 North America Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 25 North America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 26 North America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 27 North America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 28 North America Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 29 North America Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 30 North America Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 31 North America Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 32 North America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 33 North America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 34 North America Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 35 North America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 36 North America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 37 North America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 38 North America Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 39 North America Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 40 North America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 41 North America Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 42 North America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 43 North America Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 44 North America Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 45 Europe Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 46 Europe Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 47 Europe Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 48 Europe Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 49 Europe Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 50 Europe Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 51 Europe Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 52 Europe Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 53 Europe Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 54 Europe Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 55 Europe Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 56 Europe Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 57 Europe Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 58 Europe Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 59 Europe Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 60 Europe Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 61 Europe Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 62 Europe Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 63 Europe Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 64 Europe Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 65 Europe Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 66 Europe Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 67 Asia Pacific Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 68 Asia Pacific Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 69 Asia Pacific Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 70 Asia Pacific Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 71 Asia Pacific Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 72 Asia Pacific Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 73 Asia Pacific Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 74 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 75 Asia Pacific Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 76 Asia Pacific Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 77 Asia Pacific Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 78 Asia Pacific Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 79 Asia Pacific Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 80 Asia Pacific Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 81 Asia Pacific Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 82 Asia Pacific Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 83 Asia Pacific Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 84 Asia Pacific Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 85 Asia Pacific Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 86 Asia Pacific Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 87 Asia Pacific Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 88 Asia Pacific Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 89 South America Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 90 South America Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 91 South America Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 92 South America Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 93 South America Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 94 South America Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 95 South America Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 96 South America Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 97 South America Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 98 South America Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 99 South America Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 100 South America Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 101 South America Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 102 South America Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 103 South America Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 104 South America Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 105 South America Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 106 South America Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 107 South America Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 108 South America Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 109 South America Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 110 South America Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 111 Middle East & Africa Cardiac Biomarkers Market Outlook, By Country (2021-2030) ($MN)
• Table 112 Middle East & Africa Cardiac Biomarkers Market Outlook, By Product Type (2021-2030) ($MN)
• Table 113 Middle East & Africa Cardiac Biomarkers Market Outlook, By B-Type Natriuretic Peptide (BNP) (2021-2030) ($MN)
• Table 114 Middle East & Africa Cardiac Biomarkers Market Outlook, By Creatine Kinase-Muscle/Brain (CK-MB) (2021-2030) ($MN)
• Table 115 Middle East & Africa Cardiac Biomarkers Market Outlook, By High-Sensitivity C-Reactive Protein (hs-CRP) (2021-2030) ($MN)
• Table 116 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myoglobin (2021-2030) ($MN)
• Table 117 Middle East & Africa Cardiac Biomarkers Market Outlook, By Troponins (2021-2030) ($MN)
• Table 118 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 119 Middle East & Africa Cardiac Biomarkers Market Outlook, By Location of Testing (2021-2030) ($MN)
• Table 120 Middle East & Africa Cardiac Biomarkers Market Outlook, By Point-of-care Testing (2021-2030) ($MN)
• Table 121 Middle East & Africa Cardiac Biomarkers Market Outlook, By Laboratory Testing (2021-2030) ($MN)
• Table 122 Middle East & Africa Cardiac Biomarkers Market Outlook, By Application (2021-2030) ($MN)
• Table 123 Middle East & Africa Cardiac Biomarkers Market Outlook, By Myocardial Infarction (2021-2030) ($MN)
• Table 124 Middle East & Africa Cardiac Biomarkers Market Outlook, By Congestive Heart Failure (2021-2030) ($MN)
• Table 125 Middle East & Africa Cardiac Biomarkers Market Outlook, By Acute Coronary Syndrome (2021-2030) ($MN)
• Table 126 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 127 Middle East & Africa Cardiac Biomarkers Market Outlook, By End User (2021-2030) ($MN)
• Table 128 Middle East & Africa Cardiac Biomarkers Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
• Table 129 Middle East & Africa Cardiac Biomarkers Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 130 Middle East & Africa Cardiac Biomarkers Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
• Table 131 Middle East & Africa Cardiac Biomarkers Market Outlook, By Research Institutions (2021-2030) ($MN)
• Table 132 Middle East & Africa Cardiac Biomarkers Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Cardiac Biomarkers Market is accounted for $18.7 billion in 2023 and is expected to reach $54.8 billion by 2030 growing at a CAGR of 16.6% during the forecast period. Cardiac biomarkers are specific molecules or proteins released into the bloodstream due to heart injury, damage or stress. These biomarkers, such as troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP), are used in diagnostics to indicate heart-related conditions. Their detection and levels aid in diagnosing heart attacks, heart failure or other cardiac diseases, guiding treatment decisions and assessing cardiac health.

According to the World Health Organization (WHO), 77 million adults above 18 years have type 2 diabetes, with 25 million prediabetics. This increases cardiovascular disease risk and puts additional pressure on the health system.

Market Dynamics:

Driver:

Rising cardiovascular diseases

With an increasing global burden of heart-related conditions like heart attacks, heart failure and cardiac ischemia, there's a growing demand for reliable diagnostic tools. Cardiac biomarkers serve as vital indicators, aiding in the early detection, diagnosis, and prognosis of cardiovascular ailments. Their ability to accurately assess heart health, predict risks, and guide treatment strategies aligns with the pressing need for efficient, timely, and precise diagnostics in combating the rising incidence of cardiovascular diseases worldwide.

Restraint:

Stringent regulations

Stringent regulations pose a restraint on cardiac biomarker development and implementation. The rigorous approval processes set by regulatory bodies demand extensive clinical validation, often prolonging the time-to-market for new biomarkers. These stringent guidelines necessitate comprehensive studies to ensure accuracy, sensitivity and specificity in detecting cardiac conditions. Compliance with these regulations involves significant investment in research, clinical trials, and meeting specific performance criteria, leading to increased costs and time constraints.

Opportunity:

Increasing focus on point-of-care testing

Point-of-care tests allow for rapid and convenient on-site diagnostics, offering immediate results without the need for sending samples to a central laboratory. In cardiac care, this facilitates quicker detection of biomarkers like troponins, enabling faster diagnosis of heart conditions such as heart attacks. This shift enhances patient care by expediting treatment decisions, especially in emergency settings and supports healthcare systems by reducing turnaround times and improving overall efficiency in managing cardiac emergencies.

Threat:

Emergence of alternative diagnostic methods

New technologies, such as advanced imaging techniques or point-of-care testing devices, might offer rapid, non-invasive and possibly more cost-effective ways to assess cardiac health. These alternatives could challenge the dominance of traditional biomarker testing, impacting market adoption and preferences among healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic influenced cardiac biomarker testing by diverting healthcare resources towards managing the virus. Reduced non-COVID medical visits led to fewer cardiac evaluations, impacting biomarker testing frequency. Additionally, some COVID patients experienced cardiac complications, increasing the demand for biomarker assessments. The pandemic's strain on healthcare systems altered priorities, affecting cardiac biomarker utilisation and emphasising the need for adaptable diagnostic strategies during health crises.

The troponins segment is expected to be the largest during the forecast period

The troponins segment is projected to dominate due to its widespread use as a highly sensitive and specific cardiac biomarker for diagnosing heart-related conditions. Troponins, especially troponin I and troponin T, exhibit superior sensitivity in detecting myocardial injury, notably for diagnosing heart attacks. The growing prevalence of cardiovascular diseases globally and the increasing adoption of troponin testing in routine clinical practice contribute to its anticipated prominence, making it the largest segment in cardiac biomarker testing during the forecast period.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is poised for substantial growth due to increased patient access to advanced healthcare services and diagnostic facilities in hospital settings. Hospitals serve as primary centres for acute care, where cardiac biomarker testing plays a pivotal role in diagnosing heart-related conditions. Rising incidences of cardiovascular diseases and the need for timely and accurate diagnostics within hospital environments contribute to the segment's anticipated growth.

Region with largest share:

North America's anticipated dominance in the cardiac biomarkers market is attributed to well-established healthcare infrastructure, technological advancements and high healthcare spending. The region's robust research and development activities, along with the presence of key market players, contribute to its significant market share. Additionally, the high prevalence of cardiovascular diseases, coupled with increasing awareness and adoption of advanced diagnostic techniques, drives market growth.

Region with highest CAGR:

The Asia-Pacific region is poised for substantial growth in the cardiac biomarker market due to the increasing prevalence of cardiovascular diseases, a rising ageing population and improving healthcare infrastructure. The region witnesses a growing awareness of cardiac health, driving demand for advanced diagnostic tools. Additionally, initiatives by governments and healthcare organisations to enhance cardiac care contribute to the market's expansion. The increasing adoption of cardiac biomarkers in countries like China and India, along with advancements in healthcare technologies, positions the Asia-Pacific region for significant market growth.

Key players in the market

Some of the key players in Cardiac Biomarkers Market include Abbott Laboratories, Beckman Coulter, Becton, Dickinson and Company (BD), BG Medicine, Bio-Rad Laboratories, Corgenix , Fujirebio, Hologic, Meso Scale Diagnostics (MSD), Mindray, Ortho Clinical Diagnostics, Pathkind Labs, Qiagen, Randox Laboratories, R-Biopharm AG, Response Biomedical, Roche Diagnostics, Siemens Healthineers, Singulex Inc, SRL Diagnostics, Thermo Fisher Scientific and Trinity Biotech.

Key Developments:

In October 2023, Mindray has announced the introduction and global launch of two new high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions enhance Mindray's diverse portfolio of cardiac biomarkers for diagnosing and managing cardiovascular diseases (CVDs), according to a written statement issued by the global medical devices and solutions provider.

In January 2023, Pathkind Labs, Roche Diagnostics partner to release cardiac biomarker. This announcement of NTProBNP comes in light of the growing burden of heart failure among T2D patients in India, inciting the need for urgent action. NTProBNP can directly predict adverse outcomes and cardiovascular mortality and can evaluate the overall status of a patient with type 2 diabetes to facilitate the establishment of correct therapy management and follow-up.

In September 2022, SRL Diagnostics launched "Heart Assure," a specialized test that can predict the risk of a cardiac event in an individual. High-sensitivity troponin I is a simple blood test that can precisely predict a cardiac injury by providing a heart health risk score.

Product Types Covered:

• B-Type Natriuretic Peptide (BNP)
• Creatine Kinase-Muscle/Brain (CK-MB)
• High-Sensitivity C-Reactive Protein (hs-CRP)
• Myoglobin
• Troponins
• Other Product Types

Location of Testings Covered:

• Point-of-care Testing
• Laboratory Testing

Applications Covered:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Other Applications

End Users Covered:

• Diagnostic Laboratories
• Hospitals
• Pharmaceutical and Biotechnology Companies
• Research Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cardiac Biomarkers Market, By Product Type

• 5.1 Introduction
• 5.2 B-Type Natriuretic Peptide (BNP)
• 5.3 Creatine Kinase-Muscle/Brain (CK-MB)
• 5.4 High-Sensitivity C-Reactive Protein (hs-CRP)
• 5.5 Myoglobin
• 5.6 Troponins
• 5.7 Other Product Types

6 Global Cardiac Biomarkers Market, By Location of Testing

• 6.1 Introduction
• 6.2 Point-of-care Testing
• 6.3 Laboratory Testing

7 Global Cardiac Biomarkers Market, By Application

• 7.1 Introduction
• 7.2 Myocardial Infarction
• 7.3 Congestive Heart Failure
• 7.4 Acute Coronary Syndrome
• 7.5 Other Applications

8 Global Cardiac Biomarkers Market, By End User

• 8.1 Introduction
• 8.2 Diagnostic Laboratories
• 8.3 Hospitals
• 8.4 Pharmaceutical and Biotechnology Companies
• 8.5 Research Institutions
• 8.6 Other End Users

9 Global Cardiac Biomarkers Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Abbott Laboratories
• 11.2 Beckman Coulter
• 11.3 Becton, Dickinson and Company (BD)
• 11.4 BG Medicine
• 11.5 Bio-Rad Laboratories
• 11.6 Corgenix
• 11.7 Fujirebio
• 11.8 Hologic
• 11.9 Meso Scale Diagnostics (MSD)
• 11.10 Mindray
• 11.11 Ortho Clinical Diagnostics
• 11.12 Pathkind Labs
• 11.13 Qiagen
• 11.14 Randox Laboratories
• 11.15 R-Biopharm AG
• 11.16 Response Biomedical
• 11.17 Roche Diagnostics
• 11.18 Siemens Healthineers
• 11.19 Singulex Inc
• 11.20 SRL Diagnostics
• 11.21 Thermo Fisher Scientific
• 11.22 Trinity Biotech